10-K: Allurion Technologies Navigates Weight Loss Market with FDA Submission Plans and Global Expansion

Allurion Technologies plans to submit its final FDA module after positive AUDACITY trial results, resumes sales in France, and explores combination therapies to combat obesity.

Summary

• Allurion Technologies, Inc. is focused on combating obesity with its Allurion Program, featuring a swallowable intragastric balloon and AI-powered remote patient monitoring.
• The company plans to submit the final module of its premarket approval application (PMA) to the FDA based on positive results from the AUDACITY trial.
• Allurion has resumed sales of its Allurion Balloon in France after addressing regulatory concerns.
• Initial results suggest that combining the Allurion Program with low-dose GLP-1 therapy can optimize muscle mass and GLP-1 adherence, with patients experiencing an average total body weight loss of 20.3% and a 15% increase in lean body mass after 8 months.
• The global obesity treatment market is expected to reach $54 billion by 2030.
• The company estimates a $10 billion total addressable market for the Allurion Balloon in the United States.
• As of December 31, 2024, Allurion owned or had rights to 19 issued and six pending patents in the United States related to various aspects of its Allurion Balloon.
• The company's growth strategy includes deepening its global presence, launching the Allurion Program in new markets, achieving profitability, and scaling and monetizing its Virtual Care Suite (VCS).

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments such as the FDA submission plans and resumption of sales in France, the company is still operating at a loss and faces significant risks and challenges. The failure to meet the superiority margin in the AUDACITY trial is also a concern.

Positives

• The AUDACITY trial achieved its responder rate co-primary endpoint.
• The rate of serious adverse events in Allurion Balloon subjects in the AUDACITY trial was the lowest reported in a pivotal FDA trial for a liquid-filled intragastric balloon.
• Allurion is relaunching the Allurion Balloon in France after completing a remediation plan.
• Combining the Allurion Program with low-dose GLP-1 therapy resulted in an increase in lean body mass.
• The Allurion Program was designed to achieve metabolically healthy weight loss, which entails losing weight, maintaining that weight loss, and maintaining or increasing muscle mass in the process.

Negatives

• The AUDACITY trial failed to meet the co-primary endpoint on superiority margin.
• The company has incurred net operating losses in the past and expects to incur net operating losses for the foreseeable future.
• The company has a significant amount of debt, which may affect its ability to operate its business and secure additional financing in the future.
• The company depends on a limited number of single source suppliers to manufacture components, sub-assemblies, and materials, which makes it vulnerable to supply shortages and price fluctuations.

Risks

• The failure of the Allurion Balloon or the new compounded GLP-1 program to achieve and maintain market acceptance could result in achieving sales or profitability below expectations.
• There is no guarantee that the FDA or non-U.S. regulatory agencies will grant approval or clearance for current or future products.
• The weight loss and obesity-management industries are highly competitive.
• Our current international operations and any expansion of our business internationally expose us to business, regulatory, political, operational, financial, and economic risks associated with doing business internationally.
• If patients using our products experience adverse events or other undesirable side effects, regulatory authorities could withdraw or modify our regulatory approvals.

Future Outlook

The company anticipates being able to make key, strategic investments to drive growth in the future, expand gross margin, and achieve profitability.

Industry Context

The announcement comes amid increasing competition in the weight loss market, particularly with the rise of GLP-1 receptor agonists. Allurion is positioning its program as a synergistic approach that can address the limitations of these therapies, such as muscle wasting and adherence issues.

Comparison to Industry Standards

• The company compares its serious adverse event rate of 3.1% in the AUDACITY trial favorably to that of ReShape Lifesciences, Inc. (7.5%) and Apollo Endosurgery, Inc. (10%).
• The company also compares its weight loss results to those of ReShape Duo Balloon, noting that ReShape patients regained 40% of their weight loss at 48 weeks.

Related Party Transactions

• In the first quarter of 2023, Allurion entered into consulting agreements with KKG Enterprises, LLC and Remus Group Management, LLC to assist Allurion in building out its AI platform, augment its AI advisory board, and provide advisory services related to the Business Combination.
• On February 15, 2023, Allurion sold $13.0 million of 2023 Convertible Notes to HVL and entered into a Side Letter with HVL, who is a limited partner of Romulus Growth Allurion L.P., which is a fund affiliated with Krishna Gupta.
• On April 16, 2024, the company issued and sold $48 million of Notes to RTW in a private placement.
• On July 1, 2024, RTW purchased 9,594 shares of common stock and warrants to purchase 9,594 shares of common stock in the July 2024 Public Offering, for an aggregate purchase price of $0.3 million.
• On July 1, 2024, the company issued and sold 2,260,159 shares of Series A Preferred Stock and 90,407 Private Placement Warrants to funds affiliated with RTW, for an aggregate purchase price of approximately $2.7 million.
• On October 30, 2024, the company and the funds affiliated with RTW entered into the additional Revenue Interest Financing Agreement.
• On February 20, 2025, the company entered into a subscription agreement with an accredited investor affiliated with Leavitt Equity Partners LLC, pursuant to which the company agreed to sell 267,686 shares of common stock and common warrants to purchase 535,372 shares of common stock for an aggregate purchase price of approximately $1.4 million.

Stakeholder Impact

• Shareholders may experience dilution due to future sales and issuances of common stock.
• Employees may be affected by restructuring plans and workforce reductions.
• Customers may benefit from the combination of the Allurion Program with low-dose GLP-1 therapy.
• Suppliers may be affected by changes in the company's demand for components and materials.
• Creditors may be affected by the company's ability to make scheduled payments of debt principal and interest.

Next Steps

• Submit the fourth and final module of the PMA for the Allurion Balloon to the FDA.
• Perform prospective clinical trials on the combination of the Allurion Balloon and low-dose GLP-1s to further validate the effects on weight loss, muscle mass, and GLP-1 adherence.

Key Dates

Keywords

Allurion Balloon, weight loss, obesity, intragastric balloon, AUDACITY trial, GLP-1 therapy, FDA, Virtual Care Suite, patents, clinical trials